stockrow
Friday 6 November 2026
Export CBLL’s income statement to Excel — free account
CeriBell, Inc.
CBLL Healthcare Medical Devices
CeriBell, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $89.1 million, up 36.1% from fiscal 2024.
- Revenue
- +29.9%
- EPS
- −49.9%
- Free cash flow
- −19.7%
- Total debt
- +1.29%
Quarter to September 2026, against a year earlier
26.65
0.64
+2.46%
Follow CBLL
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
8.64 | 7.25 | 7.26 | 9.00 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(71.80) | (57.51) | (35.78) | (74.38) | |
P/B ratio |
7.99 | 5.77 | 4.90 | 5.16 | |
Price to Tangible BV |
7.99 | 5.77 | 4.90 | 5.16 | |
EV/Sales |
7.74 | 6.18 | 5.99 | 7.43 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(15.02) | (11.67) | (11.69) | (16.22) | |
EV/FCF |
(14.42) | (11.24) | (11.21) | (15.64) | |
Quick Ratio |
7.50 | 8.45 | 9.69 | 9.08 | |
Current Ratio |
8.18 | 9.18 | 10.44 | 9.73 | |
Net Debt/EBITDA |
4.74 | 5.39 | 5.76 | 9.41 | |
Debt/Assets |
12.79% | 12.01% | 11.18% | 10.12% | |
Debt/Equity |
0.17 | 0.16 | 0.14 | 0.13 | |
Asset Turnover |
0.61 | 0.55 | 0.49 | 0.42 | |
Operating CF/Net income |
0.61 | 0.67 | 0.98 | 0.80 | |
Capex/Depreciation |
75.50 | 0.76 | 2.57 | 2.46 | |
Interest Coverage |
(76.96) | (45.62) | (47.80) | (31.59) | |
Research and Development Expense of Revenue |
25.23% | 24.01% | 23.25% | 20.42% | |
Selling, General and Administrative Expense of Revenue |
134.57% | 139.42% | 142.32% | 125.79% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
24.19% | 21.35% | 14.05% | 13.55% | |
Graham Net Nets |
0.12 | 0.16 | 0.19 | 0.18 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(7.97%) | (9.05%) | (8.89%) | (6.70%) | |
Free Cash Flow Yield |
(6.22%) | (7.58%) | (7.35%) | (5.28%) | |
Revenue per Share |
0.76 | 0.74 | 0.70 | 0.68 | |
Operating CF per Share |
(0.34) | (0.34) | (0.51) | (0.29) | |
Capex per Share |
(0.02) | (0.01) | (0.02) | (0.02) | |
Free Cash Flow per Share |
(0.36) | (0.34) | (0.53) | (0.31) | |
Cash per Share |
3.05 | 3.40 | 3.75 | 4.36 | |
Shareholders Equity per Share |
3.05 | 3.37 | 3.74 | 4.25 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.05 | 3.37 | 3.74 | 4.25 | |
Free Cash Flow |
(13.83) | (13.09) | (20.12) | (11.33) | |
Working Capital |
129.40 | 140.65 | 152.73 | 167.53 | |
Capital Expenditures |
(0.75) | (0.22) | (0.83) | (0.55) | |
Net Current Asset Value |
108.60 | 119.81 | 131.65 | 146.25 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.03 | 0.01 | 0.03 | 0.02 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
15.01 | 14.15 | 13.51 | 12.97 | |
Average Payables |
2.26 | 2.81 | 1.68 | 1.99 | |
Average Inventory |
6.49 | 6.37 | 6.73 | 7.11 | |
Average Assets |
177.95 | 187.02 | 195.77 | 210.61 | |
Average Common Equity |
140.81 | 150.23 | 160.85 | 173.25 |
Columns are period end dates · fundamentals updated 5 Nov 2026